Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Peter C. Holm"'
Autor:
Karina Banasik, Peter L. Møller, Tanya R. Techlo, Peter C. Holm, G. Bragi Walters, Andrés Ingason, Anders Rosengren, Palle D. Rohde, Lisette J. A. Kogelman, David Westergaard, Troels Siggaard, Piotr J. Chmura, Mona A. Chalmer, Ólafur Þ. Magnússon, Guðmundur Á. Þórisson, Hreinn Stefánsson, Daníel F. Guðbjartsson, Kári Stefánsson, Jes Olesen, Simon Winther, Morten Bøttcher, Søren Brunak, Thomas Werge, Mette Nyegaard, Thomas F. Hansen
Publikováno v:
BMC Genomic Data, Vol 24, Iss 1, Pp 1-4 (2023)
Abstract Objectives Allele counts of sequence variants obtained by whole genome sequencing (WGS) often play a central role in interpreting the results of genetic and genomic research. However, such variant counts are not readily available for individ
Externí odkaz:
https://doaj.org/article/e113e373bf77483e9c84853837f696bb
Autor:
Amalie D. Haue, Jose J. Almagro Armenteros, Peter C. Holm, Robert Eriksson, Pope L. Moseley, Lars V. Køber, Henning Bundgaard, Søren Brunak
Publikováno v:
Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-13 (2022)
Abstract Background Patients diagnosed with ischemic heart disease (IHD) are becoming increasingly multi-morbid, and studies designed to analyze the full spectrum are few. Methods Disease trajectories, defined as time-ordered series of diagnoses, wer
Externí odkaz:
https://doaj.org/article/7c2c273681ec4a0e9678cf0f43f2650d
Autor:
Amalie D. Haue, Peter C. Holm, Karina Banasik, Agnete T. Lundgaard, Victorine P. Muse, Timo Röder, David Westergaard, Piotr J. Chmura, Alex H. Christensen, Peter E. Weeke, Erik Sørensen, Ole B. V. Pedersen, Sisse R. Ostrowski, Kasper K. Iversen, Lars V. Køber, Henrik Ullum, Henning Bundgaard, Søren Brunak
BackgroundThere are no methods for classifying patients with ischemic heart disease (IHD) based on the entire spectrum of pre-existing diseases. Such methods might be clinically useful due to the marked differences in presentation and course of disea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::132794147308bcbefdf5af2dc1d43373
https://doi.org/10.1101/2023.03.31.23288006
https://doi.org/10.1101/2023.03.31.23288006
Autor:
Alexander W. Jung, Peter C. Holm, Kumar Gaurav, Jessica Xin Hjaltelin, Davide Placido, Laust Hvas Mortensen, Ewan Birney, Søren Brunak, Moritz Gerstung
SummaryBackgroundHealth care is experiencing a drive towards digitisation and many countries are implementing national health data resources. Digital medicine promises to identify individuals at elevated risk of disease who may benefit from screening
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30988d3c2fa947ade1ed197822a47c8f
https://doi.org/10.1101/2022.10.12.22280908
https://doi.org/10.1101/2022.10.12.22280908
Autor:
Peter C Holm, Charlotte O'Shea, Jakob R. Winther, Kristoffer E. Johansson, Rasmus K Norrild, Martin Willemoës, Mikkel Madsen, Mathilde K Nordentoft, Jūratė Fahrig-Kamarauskaitė, Jakob Nissen, Benjamin Bjerre
Publikováno v:
Protein Engineering, Design and Selection. 32:145-151
While the field of computational protein design has witnessed amazing progression in recent years, folding properties still constitute a significant barrier towards designing new and larger proteins. In order to assess and improve folding properties
Autor:
Ina H Laursen, Karina Banasik, Amalie D Haue, Oscar Petersen, Peter C Holm, David Westergaard, Henning Bundgaard, Søren Brunak, Ruth Frikke-Schmidt, Hilma Holm, Erik Sørensen, Lise W Thørner, Margit A H Larsen, Michael Schwinn, Lars Køber, Christian Torp-Pedersen, Sisse R Ostrowski, Christian Erikstrup, Mette Nyegaard, Hreinn Stefánsson, Arnaldur Gylfason, Florian Zink, G Bragi Walters, Asmundur Oddsson, Guðmar Þorleifsson, Gisli Másson, Unnur Thorsteinsdottir, Daniel Gudbjartsson, Ole B Pedersen, Kári Stefánsson, Henrik Ullum
Publikováno v:
Laursen, I H, Banasik, K, Haue, A D, Petersen, O, Holm, P C, Westergaard, D, Bundgaard, H, Brunak, S, Frikke-Schmidt, R, Holm, H, Sørensen, E, Thørner, L W, Larsen, M A H, Schwinn, M, Køber, L, Torp-Pedersen, C, Ostrowski, S R, Erikstrup, C, Nyegaard, M, Stefánsson, H, Gylfason, A, Zink, F, Walters, G B, Oddsson, A, Porleifsson, G, Másson, G, Thorsteinsdottir, U, Gudbjartsson, D, Pedersen, O B, Stefánsson, K & Ullum, H 2021, ' Cohort profile : Copenhagen Hospital Biobank-Cardiovascular Disease Cohort (CHB-CVDC): Construction of a large-scale genetic cohort to facilitate a better understanding of heart diseases ', BMJ Open, vol. 11, no. 12, e049709 . https://doi.org/10.1136/bmjopen-2021-049709
BMJ Open
Laursen, I H, Banasik, K, Haue, A D, Petersen, O, Holm, P C, Westergaard, D, Bundgaard, H, Brunak, S, Frikke-Schmidt, R, Holm, H, Sørensen, E, Thorner, L W, Larsen, M A H, Schwinn, M, Køber, L, Torp-Pedersen, C, Ostrowski, S R, Erikstrup, C, Nyegaard, M, Stefansson, H, Gylfason, A, Zink, F, Walters, G B, Oddsson, A, Thorleifsson, G, Masson, G, Thorsteinsdottir, U, Gudbjartsson, D, Pedersen, O B, Stefansson, K & Ullum, H 2021, ' Cohort profile : Copenhagen Hospital Biobank-Cardiovascular Disease Cohort (CHB-CVDC): Construction of a large-scale genetic cohort to facilitate a better understanding of heart diseases ', BMJ Open, vol. 11, no. 12 . https://doi.org/10.1136/bmjopen-2021-049709
BMJ Open
Laursen, I H, Banasik, K, Haue, A D, Petersen, O, Holm, P C, Westergaard, D, Bundgaard, H, Brunak, S, Frikke-Schmidt, R, Holm, H, Sørensen, E, Thorner, L W, Larsen, M A H, Schwinn, M, Køber, L, Torp-Pedersen, C, Ostrowski, S R, Erikstrup, C, Nyegaard, M, Stefansson, H, Gylfason, A, Zink, F, Walters, G B, Oddsson, A, Thorleifsson, G, Masson, G, Thorsteinsdottir, U, Gudbjartsson, D, Pedersen, O B, Stefansson, K & Ullum, H 2021, ' Cohort profile : Copenhagen Hospital Biobank-Cardiovascular Disease Cohort (CHB-CVDC): Construction of a large-scale genetic cohort to facilitate a better understanding of heart diseases ', BMJ Open, vol. 11, no. 12 . https://doi.org/10.1136/bmjopen-2021-049709
PurposeThe aim of Copenhagen Hospital Biobank-Cardiovascular Disease Cohort (CHB-CVDC) is to establish a cohort that can accelerate our understanding of CVD initiation and progression by jointly studying genetics, diagnoses, treatments and risk facto